Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free RVPH Stock Alerts

Reviva Pharmaceuticals (RVPH) Earnings Date, Estimates & Call Transcripts

Reviva Pharmaceuticals logo
$0.35 -0.01 (-1.99%)
As of 05/14/2026 03:59 PM Eastern
Compare

Reviva Pharmaceuticals Earnings Summary

Reviva Pharmaceuticals posted Q1 2026 earnings on May 14, 2026, reporting an EPS of -$0.46, which missed the consensus estimate of -$0.36 by $0.11. With a trailing EPS of -$6.20, Reviva Pharmaceuticals' earnings are expected to grow next year, from ($2.96) to ($1.26) per share.

Upcoming Q2
Earnings Date
May. 21Before Market OpensEstimated
Consensus EPS
(May. 14)
-$0.36
Actual EPS
(May. 14)
-$0.46 Missed By -$0.11

Q1 2026 Earnings Resources

RVPH Upcoming Earnings

Reviva Pharmaceuticals' Q1 2026 earnings is estimated for Thursday, May 21, 2026, based on past reporting schedules

Powered by Quartr
Get Reviva Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

RVPH Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Reviva Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$1.20-$1.00-$1.10
Q2 20262-$1.20-$0.80-$1.00
Q3 20262-$1.20-$0.80-$1.00
Q4 20262-$1.40-$0.80-$1.10

Reviva Pharmaceuticals Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/21/2026
(Estimated)		--------
5/14/2026Q1 2026-$0.3550-$0.46 -$0.1050-$0.46--
11/13/2025Q3 2025-$2.20-$1.20+$1.00-$0.06--
8/14/2025Q2 2025-$3.00-$2.40+$0.60-$0.12--
5/15/2025Q1 2025-$4.20-$2.60+$1.60-$0.13--
3/31/2025Q4 2024-$4.40-$3.00+$1.40-$0.15--
8/14/2024--$5.60-$5.20+$0.40-$0.26--

Data powered by Fiscal.ai.

Reviva Pharmaceuticals Earnings - Frequently Asked Questions

Reviva Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 21st, 2026 based off last year's report dates. Learn more on RVPH's earnings history.

In the previous quarter, Reviva Pharmaceuticals (NASDAQ:RVPH) missed the analysts' consensus estimate of ($0.36) by $0.11 with a reported earnings per share (EPS) of ($0.46). Learn more on analysts' earnings estimate vs. RVPH's actual earnings.

Reviva Pharmaceuticals (NASDAQ:RVPH) has a recorded net income of -$19.86 million. RVPH has generated -$6.20 earnings per share over the last four quarters.

Reviva Pharmaceuticals' earnings are expected to grow from ($2.96) per share to ($1.26) per share in the next year.

Related Companies
Earnings Tools

This page (NASDAQ:RVPH) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel